Education
About Us
Working with TipRanks
Follow Us
Helix BioPharma (TSE:HBP)
TSX:HBP
Total Valuation
Helix BioPharma has a market cap or net worth of C$50.90M. The enterprise value is C$48.90M.
Market CapC$50.90M
Enterprise ValueC$48.90M
Share Statistics
Helix BioPharma has 53,021,538 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding53,021,538
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Helix BioPharma’s return on equity (ROE) is 102.93 and return on invested capital (ROIC) is 10265.95%.
Return on Equity (ROE)102.93
Return on Assets (ROA)-6.22
Return on Invested Capital (ROIC)10265.95%
Return on Capital Employed (ROCE)104.12
Revenue Per Employee0.00
Profits Per Employee-1.32M
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Helix BioPharma is -5.52. Helix BioPharma’s PEG ratio is 0.03.
PE Ratio-5.52
PS Ratio0.00
PB Ratio-505.92
Price to Fair Value-568.43
Price to FCF-13.84
Price to Operating Cash Flow-2.62
PEG Ratio0.03
Income Statement
In the last 12 months, Helix BioPharma had revenue of 0.00 and earned -9.26M in profits. Earnings per share was -0.21.
Revenue0.00
Gross Profit-14.00K
Operating Income-9.37M
Pretax Income-9.40M
Net Income-9.26M
EBITDA-9.38M
Earnings Per Share (EPS)-0.21
Cash Flow
In the last 12 months, operating cash flow was -3.67M and capital expenditures -4.00K, giving a free cash flow of -3.68M billion.
Operating Cash Flow-3.67M
Free Cash Flow-3.68M
Free Cash Flow per Share-0.07
Dividends & Yields
Helix BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.98
52-Week Price Change-11.93%
50-Day Moving Average0.86
200-Day Moving Average0.96
Relative Strength Index (RSI)70.10
Average Volume (3m)3.14K
Important Dates
Helix BioPharma upcoming earnings date is Jun 17, 2025, TBA Not Confirmed.
Last Earnings DateMar 14, 2025
Next Earnings DateJun 17, 2025
Ex-Dividend Date―
Financial Position
Helix BioPharma as a current ratio of 0.92, with Debt / Equity ratio of 0.00%
Current Ratio0.92
Quick Ratio0.92
Debt to Market Cap0.00
Net Debt to EBITDA0.12
Interest Coverage Ratio-1.34K
Taxes
In the past 12 months, Helix BioPharma has paid -132.00K in taxes.
Income Tax-132.00K
Effective Tax Rate0.01
Enterprise Valuation
Helix BioPharma EV to EBITDA ratio is -5.34, with an EV/FCF ratio of -9.57.
EV to Sales0.00
EV to EBITDA-5.34
EV to Free Cash Flow-9.57
EV to Operating Cash Flow-9.60
Balance Sheet
Helix BioPharma has C$2.00M in cash and marketable securities with C$0.00 in debt, giving a net cash position of -C$2.00M billion.
Cash & Marketable SecuritiesC$2.00M
Total DebtC$0.00
Net Cash-C$2.00M
Net Cash Per Share-C$0.04
Tangible Book Value Per Share>-C$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Helix BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-50.29%